Imatinib is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 809   Edition : 38,

  ►   Brandname : Gleevec,Glivec,Imatib,Zoleta

  ►  Strength :

A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral,
Reference :-   Book : Martindale    Page : 807   Edition : 38,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Chronic myeloid leukemia Oral 400 mg Daily, increased to 600 mg daily or 400 mg twice daily if required.
2 Blast crisis or accelerated phase Oral 600 mg Daily, increased to 400 mg twice daily if necessary.
3 Acute lymphoblastic leukaemia Oral 600 mg Daily may be given with induction, consolidation, or maintenance chemotherapy. The same dose may be given as monotherapy for patients with relapsed or refractory disease.
4 Gastrointestinal stromal tumours Oral 400 mg Daily and In patients with unresectable or metastatic disease that progress at this dose increase up to 400 mg twice daily may be considered.
5 Hypereosinophilia syndrome Oral 400 mg Daily.
6 Dermatofibrosarcoma protuberans Oral 400 mg b.d.
7 Myelodysplastic disease Oral 400 mg Daily.
8 Mastocytosis Oral 400 mg Daily is given, unless there is associated eosinophilia, in which case a starting dose of 100 mg daily is recommended, increased to 400 mg if response is inadequate.

Ref :-  Book : Martindale    Page : 807   Edition : 38,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Chronic myeloid leukemia Oral 340 mg/m2

Ref :- Book : Martindale    Page : 807   Edition : 38,
►  Side Effect : gastrointestinal disturbance, Myelosuppression, myalgia, arthralgia, muscle cramp, fatigue, Rashes, headache, thrombocytopenia, anaemia, Dizziness, taste disturbances, anorexia, paresthesia, insomnia, epistaxis, Cough, dyspnoea, dry skin, pruritus, alopecia, pyrexia, weakness, rigors, hepatotoxicity, hepatic necrosis, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, rhabdomyolysis, gastrointestinal bleeding, Haemorrhage, ulceration, superficial oedema, manifest as neutropenia, Eye disorder or visual disturbances, Night sweat, severe skin disorders, acute generalised exanthematous pustulosis, stromal tumor, ,
Ref :-   Book : Martindale    Page : 808   Edition : 38,

►  Drug Interaction : Drug interaction of Imatinib is with , Macrolide antibacterials, Azole Antifungal,  Rifampicin , Phenytoin , Phenobarbital , Dexamethasone , Carbamazapine ,
Ref :-   Book : Martindale    Page : 809   Edition : 38,


  ►    Mechanism of Drug Drug Interaction :  Imatinib mesilate is metabolised by the cytochrome P450 isoenzyme CYP3A4, and drugs that inhibit this enzyme, such as azole antifungals and macrolide antibacterials, may increase blood concentrations of imatinib. Equally, inducers of CYP3A4 (such as carbamazepine, dexamethasone, St John’s wort, phenobarbital, phenytoin, and rifampicin) may reduce blood concentrations of imatinib;,
Ref :-   Book : Martindale    Page : 809   Edition : 38,


►  Contraindication : , Rapid weight gain, With a history of cardiac disease , Isolated cases of left ventricular dysfunction.,
Ref :-   Book :    Page :    Edition : , Martindale    Page : 808   Edition : 38,
  ►  Mechanism of Action :   Imatinib mesilate is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia and acute lymphoblastic leukaemia. It also inhibits the tyrosine kinase for platelet-derived growth factor and stem cell factor, ckit (CD117), which is overexpressed in gastrointestinal stromal tumours ,
Ref :-   Book : Martindale    Page : 807   Edition : 38,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA


Dietry Substance Interactions


​   ► This Medicine interact with :- ST JOHNS WORT with Dietary Substance is Drug Inhibitor,

  ►  Reference :-
  • Driver, S. (2009). Stockleys Herbal Medicines Interactions. Royal pharmaceutical Society of Great Britain: Pharmaceutical press.

  •   ►  URL -- https://www.stonybrookmedicine.edu/sites/default/files/herbal_medicines_interactions-1.pdf,


    ContraIndication Dietry Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Faecal, Renal,
    Ref :-   Book : Martindale    Page : 809   Edition : 38,


    ►    Plasma Half-life :
      Min value :-   half-lives of imatinib and its major active metabolite, the N-demethylated piperazine derivative, are about 18 and 40 hours respectively.,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 809   Edition : 38,

    ►    Peak Plasma Concentration :   Min value :-   2 ,    Max value :-   4 hours,
    Ref :-   Book : Martindale    Page : 809   Edition : 38,